Increasing amounts of data suggest that affective disorders might be related to dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis, one of the stress-response systems. Arginine vasopressin (AVP) influences several symptoms, relevant to affective disorders, notable memory processes, pain sensitivity, synchronization of biological rhythms and the timing and quality of REM sleep. We examined whether genetic variations in the AVP receptor 1b gene (AVPR1b) could be associated with increased susceptibility to affective disorders using a gene-based association analysis of single-nucleotide polymorphisms (SNPs). Five SNPs were identified in AVPR1b and genotyped in two well-diagnosed samples of patients with recurrent major depression and matched controls. In the Swedish sample, we observed significant allele (P¼0.02) and genotype (P¼0.01) association with SNP AVPR1b-s3, and in the Belgian sample, a borderline significant association with SNP AVPR1b-s5 (P¼0.04). In both patient-control samples, the haplotype defined by alleles A-T-C-A-G for the AVPR1b-s SNPs s1-s2-s3-s4-s5 was significantly over-represented in controls compared to patients. Our data support a protective effect of this major haplotype for recurrent major depression.
Introduction
Studies of hypothalamic-pituitary-adrenal (HPA) function in depression reveal numerous abnormalities. These abnormalities are most pronounced in patients with melancholic features. 1 Irregularities include elevated serum and 24-h urinary free cortisol, dexamethasone nonsuppression, 2 adrenal gland hyperplasia 3 and a blunted release of adrenocorticotropin (ACTH) to corticotropin-relasing hormone (CRH) challenge. 4 These findings reflect an overactive HPA system. The underlying mechanism is most probably an increased secretion of hypothalamic CRH 5 and an increased adrenal sensitivity to ACTH. 6 These studies concentrated on CRH as the predominant ACTH secretagogue.
Gold et al 7 formulated a potential role for arginine vasopressin (AVP) in affective disorders. They postulated that AVP was a suitable candidate for involvement in complex behavioral systems, based on animal studies showing that AVP deficiency produces behavioral changes, which are reversed when the peptide is replaced. They showed that AVP was important for memory processes, pain sensitivity, synchronization of biological rhythms and the timing and quality of REM sleep, functions that are disturbed in affective disorders.
A role for AVP was supported not only by the above spectrum of symptoms but also by dynamic tests of HPA activity, in particular, the DEX/CRH test. In the DEX/CRH test, when healthy individuals are treated with dexamethasone prior to CRH infusion, the release of ACTH is blunted and the extent of blunting is proportional to the dose of DEX. 8 Paradoxically, when depressive patients were pretreated with DEX, they showed enhanced ACTH response to CRH. It was postulated that AVP-mediated ACTH release was responsible for this finding. 9 As with other peptide hormones, AVP exerts its effects through interaction with specific plasma membrane receptors, of which several subtypes have been identified. [10] [11] [12] AVP1a receptors are widely distributed on the blood vessels, and have also been found in the brain, including the paraventricular nucleus (PVN).
13 AVP2 receptors are predominantly located in the principal cells of the renal collecting system, although there is also some evidence for the brain AVP2 receptors. The ACTH-releasing properties occur via the AVP1b (V3) receptor subtype. In situ hybridization studies revealed that AVP1b receptor mRNA is expressed in the majority of pituitary corticotropes, in multiple brain regions and a number of peripheral tissues, including the kidney, heart, lung and breast and adrenal medulla.
14, 15 Sugimoto et al 16 cloned the AVP1b receptor and found that the 424-amino-acid sequence of the AVP1b receptor had the highest overall homology with the AVP1a, AVP2 and oxytocin receptors.
The aim of this study was to examine whether genetic variations in the human AVP1b receptor gene (AVPR1b) might contribute to the liability to develop affective disorders. Hereto we identified single-nucleotide polymorphisms (SNPs) in AVPR1b and subsequently analyzed them in a genetic association study in two independent samples of patients with recurrent major depression and healthy controls.
Materials and methods

Patient-control samples
Swedish sample The Swedish patient sample consisted of 89 unrelated unipolar (UP) patients. The gender ratio was 55F/34M, and the mean age at inclusion was 69.7 years78.8. Patients were diagnosed using a semistructured interview (Mini International Neuropsychiatric Interview, MINI) 17 by a trained psychiatrist, and diagnoses were made according to the Research Diagnostic Criteria. All patients had at least two well-defined episodes of major depressive disorder (average number: 3.2), as defined by DSM-IV. 18 The mean age at onset in the patient group was 37.9 years715.4. All Swedish patients were in-patients, and 27% had a personal history of suicide attempts (males: 42%; females: 58%).
The Swedish control group (n¼88) stems from the Betula project, a large population-based prospective study that has been described in detail elsewhere. 19 In this study, individuals with a lifetime history of psychotic disorders, according to a clinical interview, were excluded. The gender ratio was 54F/34M, and the mean age was 71.9 years78.6.
Patients and controls were matched for age, gender and ethnicity. All patients and controls originated from the same geographical region in the North of Sweden (County of Väserbotten), and were ascertained at the Department of Psychiatry of the University of Umeå, Sweden.
Belgian sample The Belgian patient sample consisted of 89 unrelated UP patients. The gender ratio was 67F/22M, and the mean age at inclusion was 54.6 years 713.6. Patients were diagnosed by a semistructured interview (Mini International Neuropsychiatric Interview, MINI) 17 by a trained psychiatrist and diagnoses were made according to the Research Diagnostic Criteria. All patients had at least two well-defined episodes of major depressive disorder (average number: 3.8), as defined by DSM-IV. 18 Family data were assessed using the Family History RDC instrument. 20 When available, family data were also collected from relatives. The mean age at onset in the patient group was 39.1 years717.5. In total, 71% were in-patients (males: 20%; females: 80%) and 29% were outpatients (males: 30%; females: 70%). Out of all patients, 35% had a personal history of suicide attempts (males: 18%; females: 82%). All individuals were ascertained at the Department of Psychiatry of the Erasme Hospital in Brussels, Belgium.
In the Belgian control group (n¼89), subjects with a positive personal history of psychiatric disorder were excluded using the Schedule for Affective Disorders and Schizophrenia-Lifetime Version (SADS-LA40) or the Schedule for Clinical Assessment of Neuropsychiatry (SCAN). The gender ratio was 63F/26M, and the mean age was 54.4 years714.9. The family history of psychiatric disorders was assessed using the Family History RDC instrument, 20 and individuals with first-degree relatives showing mood disorders were excluded. Patients and controls were matched for age, gender and ethnicity.
Out of all patients, 35% from both samples had a comorbid disorder (anxiety disorder or ethylabusus) (males: 15%; females: 85%). All patients and controls had grandparents of Swedish or Belgian nationality. The Medical Ethical Committees of the Universities of Umeå, Brussels and Antwerp approved the research project, and patients were included after having signed an informed consent.
SNP detection by sequencing Genomic DNAs extracted from whole blood of 24 unrelated affective disorder Belgian patients were used to detect SNPs in the AVPR1b gene. The use of DNA of patients is expected to increase the likelihood that rare SNPs, over-represented in patients, are detected. Primer pairs were used to amplify the two exons, 1 kb of the 5 0 upstream regulatory region and 0.5 kb of the 3 0 downstream region of AVPR1b (GenBank acc. no. NM_000706). Approximately 50 ng of genomic DNA and 10 pmol of each primer were used in a standard PCR reaction. The primer sequences are available upon request. Direct sequencing of PCR products was performed using the Big Dye terminator cycle sequencing kit (Applied Biosystems, PE), according to the manufacturer's protocol. Sequencing reactions were run on an ABI 3700 automated sequencer. Data were collected and analyzed using the ABI DNA sequencing software version 3.6. SNPs were identified using the SeqManII software version 4 (DNASTAR Inc.).
SNP analysis by pyrosequencing Biotinylated PCR products were immobilized onto streptavidin-coated Genetic association of AVP1b receptor with recurrent major depression D van West et al paramagnetic beads (Dynal AS, Oslo, Norway). Biotinylated ssDNA was obtained by incubating the immobilized PCR product in 50 ml 0.5 M NaOH for 5 min followed by two sequential washes in 100 ml 10 mM Tris-acetate pH 7.6. Primer annealing was obtained by incubation at 801C for 2 min and then at room temperature for 5 min. Pyrosequencing was performed on the LUC96 pyrosequencer (Pyrosequencing AB, Uppsala, Sweden).
Statistical analysis The GENEPOP program 21 was used to compare the overall allele and genotype distributions for each SNP in UP patients and controls and to test Hardy-Weinberg equilibrium. To estimate SNP haplotype frequencies in patients and controls, the expectation maximization (EM) algorithm provided by the Arlequin package 22 was applied. Given the sample size in both study groups, the a priori power to detect a 1.8-fold difference in the frequency of an allele with a frequency of 25% is 80% (a¼0.05; two-sided). The a priori power to detect a 2.2-fold difference in the frequency of an allele with a frequency of 10% is 80% (a¼0.05; two-sided). Figure 1 ). The five SNPs were subsequently genotyped by pyrosequencing in two independently ascertained patient-control samples of northern Swedish and Belgian origin (Tables 2 and 3 ). In both control populations, the allele and genotype distributions of all five SNPs were in Hardy-Weinberg equilibrium. The minor allele frequencies of the five SNPs varied from 4 to 27% in the northern Swedish, and from 4 to 14% in the Belgian control population (Table 2) . When comparing the allele and genotype frequencies in the two control populations, significant differences were observed for two SNPs: APVR1b-s3 (allelic Po0.001, genotypic Po0.001) and APVR1b-s4 (allelic P¼0.004, genotypic P¼0.007).
Results
SNP detection and genotyping
SNP association analysis
In the Swedish patient-control sample, a significant difference in allele distribution between patients and controls was observed for AVPR1b-s3 (P¼0.026) (Table 2a) , with the major allele C more frequent in controls. For the Belgian patient-control sample, a borderline significant allelic difference was observed for AVPR1b-s5 (P¼0.043) (Table 2b) , with the major allele G more frequently present in the controls. In the genotype distributions, this is reflected by a significant increase of CC homozygotes of AVPR1b-s3 in the Swedish controls (P¼0.014) (Table 3a) , and of GG homozygotes of APVR1b-s5 in the Belgian controls, although not significant (P¼0.078) (Table 3b) .
SNP haplotype analysis
We estimated the SNP haplotype frequencies in patients and controls using the EM algorithm embedded in the program Arlequin. In the Swedish patient-control sample, six haplotypes represented 488% of the total haplotype diversity present in the Figure 1 Schematic representation of the localization of the five SNPs in the 12 kb genomic region of AVPR1b (Table 1) . Genetic association of AVP1b receptor with recurrent major depression D van West et al control population (Figures 2a) . The overall distribution of the six haplotypes was significantly different between patients and controls (P¼0.002 by w 2 analysis). The haplotype with major alleles A-T-C-A-G, for respectively the five SNPS of AVPR1b-s1-s2-s3-s4-s5, had an estimated frequency of 53% in controls and 42% in patients. Carrying this major haplotype decreased the probability of developing UP in this population (OR¼0.52, 95% confidence interval (CI) 0.33-0.81). In the Belgian patient-control sample, five haplotypes represented 495% of all haplotypes in the control population (Figure 2b) . The overall distribution of these five haplotypes was significantly different between patients and controls (P¼0.0003 by w 2 analysis). The major haplotype had an estimated frequency of 88% in controls and 74% in patients. This is the same haplotype that was over-represented in controls in the Swedish population. Carrying this haplotype decreased the probability of developing UP in the Belgian population (OR¼0.28, 95% CI 0.14-0.54).
When analyzing the samples separately for the male and the female subgroups, the total haplotype distribution was significantly different between female patients and controls in both the Swedish and Belgian samples, due to the decreased frequency of the A-T-C-A-G haplotype in patients. In the Swedish and Belgian male groups, the haplotype distribution did not significantly differ in patients vs controls, although in both groups the same haplotype was under-represented in patients. However, the power in both male samples to detect significant differences was small (n = 22 and 35 respectively).
Discussion
By evaluating haplotypes, rather than single-locus tests of association, the loss of information attributable to biallelic rather than multiallelic loci can be compensated, possibly resulting in an increased informativity. The use of haplotype frequency estimation from unphased SNP genotype data provides an accurate way of inferring phase information from unrelated individuals. 23 The method used in this paper is very similar to the one proposed by Zhao et al 24 and by Fallin et al. 25 This method consists of an estimation of haplotype frequencies using an EM algorithm, followed by a w 2 analysis or a likelihood ratio test. In the Fallin paper, both steps were combined into one program (which is not publicly available). In the Zhao study, as in this paper, both steps were performed separately. As shown in several studies, the reliability of this statistical procedure to infer haplotypes from diploid data with unknown phase is excellent. 26, 27 Hence, we describe the construction and analysis of an SNP map consisting of five SNPs along the 12-kblarge AVP1b receptor gene. We compared allele and genotype frequencies of the five SNPs in Swedish and Belgian UP patients and controls. In the Swedish sample, we observed allele and genotype association with SNP AVPR1b-s3; the G-allele is more frequent in patients than in controls. Accordingly, a haplotype with alleles A-T-C-A-G for polymorphisms s1-s2-s3-s4-s5 (so without the G-allele for AVPR1b-s3) was significantly over-represented in controls compared to patients. In the Belgian sample, we found no association with AVPR1b-s3 probably because the Gallele is rare in this population. However, also in this independent population, the same A-T-C-A-G haplotype is over-represented in controls. This is consistent with the finding of an increased frequency in controls of the G-allele for SNP AVPR1b-s5 in the Belgian population.
The individual SNP association findings would not withstand correction for multiple comparisons. However, the difference in the global haplotype distribution is highly significant in both patient and control populations and is caused by the over-representation in controls of the same SNP haplotype. The data suggest that this haplotype is associated with a decreased probability of major depression in both the samples.
The Swedish and the Belgian study separately were each at risk of false-positive findings (due to relatively small sample size), but it is unlikely that two falsepositive findings would occur in two independent populations with an identical SNP haplotype at the same functional candidate gene.
Since all SNPs are intronic and some distance away from the intron-exon boundaries, it is unlikely that any of these SNPs is the actual protective mutation. It is more likely that the associated SNP haplotype is in LD with a sequence variant in the 5 00 regulatory region that influences the expression of the AVP1b receptor gene. It is known that the AVPR1B gene contains a CRE motif. CREB1 has recently been reported to exhibit significant evidence of linkage to UP depressive disorders in families identified by probands with recurrent, early-onset UP patients. 28 The linkage was sex-limited and was observed only in women. Since, our AVPR1b findings are also more robust in women compared to men, we could speculate on a potential relevance of the CRE site in the AVPR1b promoter region.
For 58 Swedish UP patients, DST data were available. The AVPR1b-s3 was not related to cortisol suppression after DEX challenge. It should be mentioned that DST is not a very accurate test to measure the HPA axis hyperdrive, and that the availability of a DEX/CRH test would have allowed a more comprehensive evaluation of the HPA axis.
Several studies can be designed to follow up on the AVPR1b association finding. Although in both control populations genotype distributions for all five SNPs were in HWE, it cannot be excluded that they are not fully representative for the genotype frequencies in the general population. More studies are needed to determine these frequencies beyond discussion. The association should be replicated in other independent patient-control samples. Second, patients and controls carrying the associated haplotype might be tested with sensitive HPA axis functional tests, such as the combined DEX/CRH test, in order to assess the consequences on the HPA axis negative feedback function.
